In an experiment using the APPSw transgenic AD mouse model, both intraperitoneal (i.p.)injection (20 mg/kg) for 60 days and orally treated EGCG (50 mg/kg) for six months regulated the tau protein profile and markedly suppressed the phosphorylated tau isoforms [52]. This evidence concerns the gene MAPT and Alzheimer disease.